1
Total investments
0
Early stage
0
Mid stage
0
Late stage
13y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
E
Investor and Public Relations Consultant
May 2013
Epizyme, Inc. is a late-stage biopharmaceutical company rewriting therapy for cancer and other serious diseases through novel epigenetic medicines.
Our pipeline is led by tazemetostat, an investigational agent that is an orally administered, first-in-class small molecule EZH2 inhibitor for the treatment of multiple types of hematological malignancies and genetically defined solid tumors.
The company also is developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them.
For more information, visit www.epizyme.com.
Experience · 1 entries
All (1)
Investments (1)
2013
E
Investor and Public Relations Consultant
May 2013
Epizyme, Inc. is a late-stage biopharmaceutical company rewriting therapy for cancer and other serious diseases through novel epigenetic medicines.
Our pipeline is led by tazemetostat, an investigational agent that is an orally administered, first-in-class small molecule EZH2 inhibitor for the treatment of multiple types of hematological malignancies and genetically defined solid tumors.
The company also is developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them.
For more information, visit www.epizyme.com.